Valuation: Fusion Antibodies plc

Market Cap 13.14M 17.93M 15.37M 14.37M 24.8M 1.72B 25.06M 170M 66.14M 862M 67.32M 65.86M 2.85B P/E 2026 *
-15x
P/E 2027 * -11.7x
Enterprise Value 13.14M 17.93M 15.37M 14.37M 24.8M 1.72B 25.06M 170M 66.14M 862M 67.32M 65.86M 2.85B EV / Sales 2026 *
6.16x
EV / Sales 2027 * 6.26x
Free-Float
87.63%
Yield 2026 *
-
Yield 2027 * -
1 week+2.44%
Current month+7.69%
1 month-2.33%
3 months-19.23%
6 months-25.00%
Current year-25.00%
1 week 10
Extreme 10
11
1 month 9.5
Extreme 9.5
11.5
Current year 9.5
Extreme 9.5
17
1 year 9.5
Extreme 9.5
21
3 years 2.8
Extreme 2.8
21
5 years 2.8
Extreme 2.8
138
10 years 2.8
Extreme 2.8
250
Manager TitleAgeSince
Chief Executive Officer 59 2022-08-14
Director of Finance/CFO 52 2023-08-23
Chief Operating Officer - 2023-09-30
Director TitleAgeSince
Chairman 68 2011-08-31
Director/Board Member 50 2011-08-31
Director/Board Member 71 2006-12-31
Date Insider Type Main position Quantity % Market Cap.
2/17/26 Others

Chairman

200,000 0.1760%
1/27/26 Free

Chief Technology Officer

125,282 0.1102%
1/27/26 Free

Chief Executive Officer

183,438 0.1614%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.44%-30.00%+75.00% 17.93M
+0.78%+4.77%+3.49%+25.25% 51.21B
+1.01%-0.20%+471.68%+564.93% 45.35B
+0.16%+7.88%+36.14%+20.76% 42.84B
-0.66%+2.61%+18.59%+87.04% 42.29B
+0.88%-3.48%+17.20%+53.83% 32.15B
-0.12%+3.84%+33.73%+145.25% 17.31B
-0.53%+1.84% - - 16.55B
+0.14%+5.37%+9.98%+31.40% 14.84B
+1.15%+4.17%+84.49%+50.33% 14.25B
Average +0.29%+2.91%+71.70%+117.09% 27.68B
Weighted average by Cap. +0.37%+3.07%+101.41%+141.83%

Financials

2026 *2027 *
Net sales 2.14M 2.91M 2.5M 2.34M 4.03M 279M 4.07M 27.63M 10.74M 140M 10.94M 10.7M 463M 2.1M 2.87M 2.46M 2.3M 3.96M 274M 4.01M 27.18M 10.57M 138M 10.76M 10.52M 456M
Net income -757K -1.03M -885K -828K -1.43M -98.89M -1.44M -9.8M -3.81M -49.66M -3.88M -3.79M -164M -1.1M -1.5M -1.28M -1.2M -2.07M -143M -2.09M -14.19M -5.52M -71.89M -5.61M -5.49M -238M
Net Debt - -
Logo Fusion Antibodies plc
Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The Company offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development. It offers a range of services including antibody discovery/generation, development, characterization, optimization, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanization using Fusion's proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for downstream use by the customer to produce material for clinical trials. Its Integrated Therapeutic Antibody Services (ITA) offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Employees
24
Date Price Change Volume
26-08-25 GBX 10.50 0.00% 0
26-08-24 GBX 10.50 0.00% 124,447
26-08-21 GBX 10.50 +2.44% 239,634
26-08-20 GBX 10.25 0.00% 237,034
26-08-19 GBX 10.25 0.00% 348,925

Quarterly revenue - Rate of surprise